These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
65145-0118 Market Analysis and Financial Projection
The drug with NDC 65145-0118, manufactured by Caplin Steriles Limited, is an injectable form of sumatriptan, a medication primarily used for acute migraine treatment. Below is a detailed market analysis and price projection for this product:
Market Analysis
Current Market Landscape
Demand Drivers:
Rising global prevalence of migraines, affecting over 29.5 million people in the U.S. alone[11][13].
Growing preference for non-opioid, fast-acting treatments, with injectable sumatriptan providing relief in as little as 10 minutes[11][13].
Expansion of telemedicine improving access to prescriptions[6].
Market Size:
The global injectable sumatriptan market was valued at $1.2 billion in 2022, with a projected CAGR of 4.8%–6.5% through 2030, reaching $1.8–$2.5 billion[3][8][6].
In the U.S., injectable sumatriptan accounts for 8% of the triptan market, generating $381 million annually[11][13].
Competitive Landscape:
Key players include GlaxoSmithKline, Pfizer, Teva, and Sun Pharma[3][4].
Caplin Steriles has shown 71% YoY revenue growth in its U.S. injectables segment, supported by 25 ANDA approvals and a pipeline of 40+ products[16].
Price Trends and Projections
Current Pricing
Injectable sumatriptan prices vary by formulation and strength:
Subcutaneous injection (6 mg/0.5 mL): ~$54–$57 per unit[17].
Nasal spray (20 mg): ~$22–$54 per unit[12][17].
Factors Influencing Pricing
Generic Competition: As a generic drug, sumatriptan faces pricing pressure. However, specialized delivery systems (e.g., autoinjectors) may command premiums[12][14].
Manufacturing Expansion: Caplin Steriles’ $650–700 million capex for new production lines could improve economies of scale, potentially stabilizing prices[16].
Regulatory and Reimbursement Policies: Favorable policies for biosimilars in North America may drive competition and moderate price growth[2].
2025–2030 Projections
Prices are expected to grow 2–4% annually, in line with healthcare inflation and demand for advanced delivery systems.
By 2030, injectable sumatriptan could average $60–$65 per unit, assuming steady generic competition and Caplin’s market penetration[6][16].
Strategic Opportunities
Emerging Markets: Asia-Pacific and Latin America offer growth potential due to expanding healthcare infrastructure[3][8].
Innovative Delivery Systems: Investment in needle-free technologies (e.g., autoinjectors) could capture higher-margin segments[11][13].
Biosimilar Development: Partnerships to launch interchangeable biosimilars may disrupt market dynamics[2][4].
“Injectable sumatriptan’s rapid efficacy positions it as a critical tool in migraine management, with sustained demand in both established and emerging markets.” – Market Research Report[8]
This analysis reflects Caplin Steriles’ strategic positioning in a growing market, balancing competitive pricing with innovation-driven opportunities.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
